Adherence to Medications for the Treatment of Osteoporosis

Rheumatic Disease Clinics of North America

Volumn 32, Issue 4, 2006, Pages 721-731

  Silverman, Stuart ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

AMNESIA; BONE DENSITY; CLINICAL TRIAL; CORTICOSTEROID INDUCED MYOPATHY; DRUG DOSE REGIMEN; HUMAN; MEMORY DISORDER; META ANALYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW;

HUMANS; OSTEOPOROSIS; PATIENT COMPLIANCE;

EID: 34247276595     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2006.07.003     Document Type: Review

References (40)

1. Sclar D.A., Chin A., Skaer T.L., et al. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther 13 4 (1991) 489-495
2. Cramer J.A., Amonkar M.M., Hebborn A., et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21 9 (2005) 1453-1460
3. Sikka R., Xia F., and Aubert R.E. Estimating medication persistency using administrative claims data. Am J Manag Care 11 7 (2005) 449-457
4. Dezii C.M. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 10 2 (2001) 42-45
5. Hart J.T. Commentary: can health outputs of routine practice approach those of clinical trials?. Int J Epidemiol 30 6 (2001) 1263-1267
6. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 5 (2005) 487-497
7. Benner J.S., Glynn R.J., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 188 (2002) 455-461
8. Roe C.M., Motherall B.R., Teitelbaum F., et al. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J 138 (1999) 818-825
9. Ghali J.K., Kadakia S., Cooper R., et al. Precipitating factors leading to decompensation of heart failure: traits among urban blacks. Arch Intern Med 148 (1988) 2013-2016
10. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 8 (2001) 1296-1310
11. Miller N.H. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102 2A (1997) 43-49
12. Tosteson A.N., Grove M.R., Hammond C.S., et al. Early discontinuation of treatment for osteoporosis. Am J Med 115 3 (2003) 209-216
13. Hamilton B., McCoy K., and Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14 3 (2003) 259-262
14. McCombs J.S., Thiebaud P., McLaughlin-Miley C., et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 3 (2004) 271-287
15. Simon J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for once weekly alendronate 70 mg versus once daily alendronate 10 mg: a multicenter randomized open label crossover study. Clin Ther 24 (2002) 1871-1886
16. Simon J.A., Beusterien K., Leidy N.K., et al. Women with postmenopausal osteoporosis express a preference for once-monthly versus once-weekly bisphosphonate treatment. Female Patient 30 (2005) 31-36
17. Ettinger M., Gallagher R., Amonkar M., et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 50 (2004) S513
18. Boccuzzi SF, Omar SH, Kahler MA, et al. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Presented at the European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO), Rome, Italy. March 16-19, 2005.
19. Recker R.R., Gallagher R., and Mac Cosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80 (2005) 856-861
20. Curtis J.R., Westfall A.O., Allison J.J., et al. Persistence and adherence to alendronate and risedronate among chronic glucocorticoid users. [abstract]. Arthritis Rheum 52 9 Suppl (2005) s374
21. O'Brien M.K., Petrie K., and Raeburn J. Adherence to medication regimens: updating a complex medical issue. Med Care Rev 49 4 (1992) 435-454
22. Bender B., Milgrom H., and Rand C. Nonadherence in asthmatic patients: is there a solution to the problem?. Ann Allergy Asthma Immunol 79 3 (1997) 177-185 [quiz 185-6]
23. Granger B.B., Swedberg K., Ekman I., et al., for the CHARM investigators. Adherence to candesartan and placebo and outcomes in congestive heart failure in the CHARM programme: double blind, randomized controlled trial. Lancet 366 (2005) 2005-2011
24. Col N., Fanale J.E., and Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 150 4 (1990) 841-845
25. Gold D.T., and Silverman S.L. Osteoporosis self-management: Choices For Better Bone Health. South Med J 97 6 (2004) 551-554
26. Yood R.A., Emani S., Reed J.I., et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14 12 (2003) 965-968
27. Clowes J.A., Peel N.F., and Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89 3 (2004) 1117-1123
28. Caro J.J., Ishak K.J., Huybrechts K.F., et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 12 (2004) 1003-1008
29. Siris E., Harris S.T., Rosen C., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women. Relationship to vertebral and non-vertebral fractures from a US claims database. Mayo Clin Proc 81 8 (2006) 1013-1022
30. McDonald K., Ledwidge M., Cahill J., et al. Elimination of early rehospitalization in a randomised, controlled trial of multidisciplinary care in a high risk elderly heart failure population. Eur J Heart Fail 3 (2001) 209-215
31. Irvine J., Baker B., Smith J., et al. Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Psychosom Med 61 (1999) 566-575
32. Pickney C.S., and Arnason J.A. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 16 9 (2005) 1156-1160
33. IPSOS Health. European Survey of Physicians and Women with Osteoporosis. Sponsored by Roche-GSK. January-April 2005.
34. Roth M.T., and Ivey J.L. Self reported medication use in community residing older adults: a pilot study. Am J Geriat Pharmacother 3 (2005) 196-204
35. Papaioannou A., Ioannidis G., Adachi J.D., et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14 10 (2003) 808-813
36. Solomon D.H., Avorn J., Katz J.N., et al. Compliance with osteoporosis medications. Arch Intern Med 165 20 (2005) 2414-2419
37. Haynes R.B., Yao X., Degani A., et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 4 (2005) CD000011
38. Bissell P., May C.R., and Noyce P.R. From compliance to concordance: barriers to accomplishing a re-framed model of health care interactions. Soc Sci Med 58 (2004) 851-862
39. Nattras S, Silverman S, Drinkwater B. Effectiveness of education and/or NTx results as a means of encouraging compliance to alendronate. Presented at World Congress on Osteoporosis, Chicago, Illinois. June 15-18, 2000
40. Delmas P.D., Vrijens B., Roux C., et al. Reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: The IMPACT Study. J Bone Miner Res 18 Suppl 2 (2003) S374